Z-021

Ziprasidone hydrochloride solution

1 mg/mL ((as free base), Methanol:DMSO (80:20) (m/m)), certified reference material, ampule of 1 mL, Cerilliant^®

• Formule empirique (notation de Hill): C₂₁H₂₁ClN₄OS · HCl
• Numéro CAS: 122883-93-6
• Poids moléculaire : 449.40
• Numéro MDL: MFCD06795476
• Code UNSPSC : 41116107
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: certified reference material
• Niveau de qualité: 300
• Caractéristiques: Snap-N-Spike^®/Snap-N-Shoot^®
• Conditionnement: ampule of 1 mL
• Fabricant/nom de marque: Cerilliant^®
• Concentration: 1 mg/mL ((as free base), Methanol:DMSO (80:20) (m/m))
• Format: single component solution
• Température de stockage: -10 to -25°C
• InChI: 1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2
• Clé InChI: ZCBZSCBNOOIHFP-UHFFFAOYSA-N

Description

Description générale

A Certified Spiking Solution^® applicable to use in forensic drug analysis or calibrator preparation by LC/MS or GC/MS. Ziprasidone is sold under the trade names Geodon and Zeldox for treatment of schizophrenia and bipolar disorder. Recent studies have suggested that Ziprasidone may increase the risk of Type II diabetes and hyperglycemia.

Application

• Enhanced Drug Delivery Systems: A study detailed the development of sustained-release ziprasiDonemicroparticles using Soluplus and ethyl cellulose. This formulation aims to eliminate the food effect and enhance bioavailability, marking a significant advancement in pharmaceutical formulations for schizophrenia treatment (Liu W et al., 2019).


• Targeted CNS Delivery:The study evaluated the brain-targeting and antipsychotic activities of nasally administered ziprasiDonethrough lipid-polymer hybrid nanocarriers. This novel delivery method could revolutionize treatment approaches in psychiatric medicine by enhancing drug efficacy and patient compliance in schizophrenia management (Abo El-Enin HA et al., 2023).


• Real-world Effectiveness in Bipolar Disorder:The study conducted a register-based national cohort study on the real-world effectiveness of pharmacological treatments for bipolar disorder, including ziprasidone. This research provides valuable insights into the therapeutic impacts and side effect profiles of ziprasiDonein a large patient population (Lahteenvuo M et al., 2023).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Pictogrammes: GHS02,GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H225,H301 + H311 + H331,H370
• Conseils de prudence: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• Classification des risques: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Organes cibles: Eyes,Central nervous system
• Code de la classe de stockage: 3 - Flammable liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): 71.6 °F
• Point d'éclair (°C): 22 °C